

Accelerating growth and creating value

Peter Löscher / Joe Kaeser

July 25, 2007


Safe Harbour Statement

This document contains forward-looking statements and information – that is, statements related to future, not past, events. These statements may be identified by words as “expects,” “looks forward to,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. Such statements are based on our current expectations and certain assumptions, and are, therefore, subject to certain risks and uncertainties. A variety of factors, many of which are beyond Siemens’ control, affect its operations, performance, business strategy and results and could cause the actual results, performance or achievements of Siemens worldwide to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. For us, particular uncertainties arise, among others, from: changes in general economic and business conditions (including margin developments in major business areas); the challenges of integrating major acquisitions and implementing joint ventures and other significant portfolio measures; changes in currency exchange rates and interest rates; introduction of competing products or technologies by other companies; lack of acceptance of new products or services by customers targeted by Siemens worldwide; changes in business strategy; the outcome of pending investigations and legal proceedings; our analysis of the potential impact of such matters on our financial statements; as well as various other factors. More detailed information about our risk factors is contained in Siemens’ filings with the SEC, which are available on the Siemens website, www.siemens.com, and on the SEC’s website, www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the relevant forward-looking statement as expected, anticipated, intended, planned, believed, sought, estimated or projected. Siemens does not intend or assume any obligation to update or revise these forward-looking statements in light of developments which differ from those anticipated.

Key figures – third quarter of FY 2007

In millions of Euros	Q3 FY07	Δ (in %, except for EPS)	Q3 FY06
New orders	22,147	+13	19,656
Revenue	20,176	+8	18,689
Group profit from Operations	1,504	+22	1,231
Net income	2,065	+54	1,344
Earnings per share (EPS) (in €, not diluted; change in €)	2.25	+0.8	1.45
Free cash flow (continuing operations)	908	—	850

Driving performance by further sharpening focus and building a strong portfolio




Leading businesses in attractive application fields

High quality of our businesses

PG	PTD	Osram	A&D	I&S	SBT	TS	SV	MED	SIS
----	-----	-------	-----	-----	-----	----	----	-----	-----

#1 or #2 position

Attractive markets with tailwind from megatrends



Application fields



Energy & Environmental Care

€21 bn¹⁾



Automation & Control Industrial & Public Infrastructures

€41 bn¹⁾



Healthcare

€8 bn¹⁾

1) Sales 2006; E&E: PG, PTD, Osram; A&C: A&D, I&S, SBT, TS, SV; H: Med; without consolidation effects; SIS cross functional offering, not considered; Other Ops excluded

Sale of Siemens VDO to Continental creates significant shareholder value

Deal structure

- **Straight sale** of 100% of shares of Siemens VDO Automotive AG to Continental AG
- **Significant value upside** compared to IPO
- **Enterprise value** of **€11.4 bn** (incl. €0.4 bn debt)
 - LTM¹⁾-multiples EV/Sales: 1.1x, EV/EBITDA: 11.3x
- **Closing** expected by **end of CY 2007** (subject to approval by the responsible antitrust authorities)

Strategic rationale

- **More focused portfolio** with **reduced complexity**
- Benefiting from **industry consolidation**
- **Free up capital** to invest in high-growth and higher ROCE businesses
- **Excellent perspectives** for Siemens VDO and its employees

Impact on Siemens

- **Cash available to return to shareholders**
(repurchase of convertible, EPS dilution through reduction of 25 million shares)
- **Cash available** to reinvest in **high return businesses**
- **Cash available** to reinvest in our **core application fields:**
Energy, Industry, Healthcare

1) LTM: last twelve months

Acquisition of Dade Behring to strengthen Siemens portfolio

Deal structure

- Intention to submit a **public take over bid** over 100% of Dade Behring shares at **US\$77 per share** amounting to approx. 7 bn US\$ or €5 bn
- Expected **closing Q2 FY 2008** (subject to receipt of regulatory approvals and other customary closing conditions)

Strategic rationale

- Significant next step in our strategy to create the **leading integrated diagnostics company**
- Achieving **leadership in attractive In Vitro Diagnostics market**
- Highly **complementary product and technology portfolios** and excellent fit of lab customer base
- **High synergies** in all relevant processes with a net present value of €1.8 bn¹⁾ (synergy savings increasing from €160 million per year from 2010)


Impact on Siemens

- **EPS accretive** as of 2010
- **Improving EBIT margin** of Siemens Medical Solutions by 2009
- Strengthening Siemens' position in **highly profitable and high growth** healthcare sector

1) after one-time costs


Outlook – Further portfolio strengthening for value creation

Leading businesses in attractive markets



- **Strengthening strongest businesses in attractive markets** (strong market growth, high earnings potential, low market volatility)
- Further develop **leading positions of businesses** (above-market sales growth, high earnings, leading market position)

High capital efficiency



- Increased focus on **capital efficiency** and **cash conversion**
- Committed to providing **shareholder return**


Key financial figures of Q3 FY 2007

Joe Kaeser

New orders – Strong 13% growth

Groups	Q3 FY07 (in m €)	Δ (in %)
SIS	1,094	(8)
A&D	4,270	19
I&S	2,502	43
SBT	1,269	11
PG	3,942	59
PTD	2,392	15
TS	658	(58)
SV	2,719	5
Med	2,517	21
Osram	1,124	3


Regions	Q3 FY07 (in m €)	Δ (in %)
Europe excl. Germany	6,558	14
Germany	3,488	0
Americas	6,275	10
Asia-Pacific	3,762	43
Middle East / C.I.S. / Africa	2,064	(2)



Revenue up 8% – Outstanding growth in A&D, Med, PTD, and PG

Groups	Q3 FY07 (in m €)	Δ (in %)
SIS	1,257	3
A&D	3,885	19
I&S	2,149	(4)
SBT	1,161	3
PG	2,863	9
PTD	1,922	12
TS	1,006	2
SV	2,731	5
Med	2,431	32
Osram	1,124	3

Regions	Q3 FY07 (in m €)	Δ (in %)
Europe excl. Germany	6,226	11
Germany	3,589	0
Americas	5,468	4
Asia-Pacific	3,140	19
Middle East / C.I.S. / Africa	1,753	11



Majority of Groups already in Fit for 2010 margin ranges

Groups	Profit margin Q3 FY07 IFRS	Fit for 2010 Margin ranges
SIS	5.3%	5-7%
A&D	13.1%	12-15%
I&S	4.4%	5-7%
SBT	6.9%	7-9%
PG	10.1%	10-14%
PTD	7.9%	7-10%
TS	2.4%	5-7%
SV	7.8%	7-9%
Med	12.6%	13-15%
Osram	10.3%	10-12%
SFS*	21.9%	20-23%

* Return on equity

First nine months FY 2007 – strong Group profit increase

- New orders **+8% (€70.198 bn)**
- Revenue **+8% (€59.870 bn)**
- Group profit from Operations **+41% (€5.1 bn)**
- Net income **+28% (€4.1 bn)**

Key figures – First nine months FY 2007

	2007 (in m €)	Δ (in %, except for EPS)	2006 (in m €)
New orders	70,198	+8	64,852
Revenue	59,870	+8	55,489
Group profit from Operations	5,099	+41	3,622
Net income	4,112	+28	3,206
Earnings per share (EPS) (in €, not diluted; change in €)	4.43	+1.00	3.43
Free cash flow (continuing operations)	3,258	—	958

Reconciliation and Definitions for Non-GAAP Measures (I)

Group profit from Operations is reconciled to Income before income taxes of Operations under Reconciliation to financial statements on the table Segment information. See our Financial Publications at our Investor Relations website under www.siemens.com.

Return on Capital Employed (ROCE) is a measure of how capital invested in the Company or the Group yields competitive returns. For the **Company**, **ROCE** is calculated as Net income (before interest) divided by average Capital employed (CE). Net income (before interest) is defined as Net income excluding Other interest income (expense), net and excluding taxes on Other interest income (expense), net. Taxes on Other interest income (expense), net are calculated in simplified form by applying the current tax rate which can be derived from the Consolidated Statements of Income, to Other interest income (expense), net. CE is defined as Total equity plus Long-term debt plus Short-term debt and current maturities of long-term debt minus Cash and cash equivalents.

Because Siemens reports discontinued operations, Siemens also calculates ROCE on a continuing operations basis, using Income from continuing operations rather than Net income. For purposes of this calculation, CE is adjusted by the net figure for Assets classified as held for disposal less Liabilities associated with assets classified as held for disposal.

For the **Operations Groups**, **ROCE** is calculated as Group profit divided by average Net capital employed (NCE). Group profit for the Operations Groups is principally defined as earnings before financing interest, certain pension costs and income taxes. Group profit excludes various categories of items which are not allocated to the Groups since the Managing Board does not regard such items as indicative of the Groups' performance. NCE for the Operations Groups is defined as total assets less tax assets, provisions and non-interest bearing liabilities other than tax liabilities.

Average (Net) Capital employed for the fiscal year is calculated as a "five-point average" obtained by averaging the (Net) Capital employed at the beginning of the first quarter plus the final figures for all four quarters of the fiscal year. For the calculation of the average during for the quarters, see below:

Average calculation for CE*:

Year-to-Date	
Q1	2 Point average: $(\text{CE ending Q4 Prior year} + \text{CE ending Q1}) / 2$
Q2	3 Point average: $(\text{CE ending Q4 Prior year} + \text{CE ending Q1} + \text{CE ending Q2}) / 3$
Q3	4 Point average: $(\text{CE ending Q4 Prior year} + \text{CE ending Q1} + \text{CE ending Q2} + \text{CE ending Q3}) / 4$

Quarter-to-Date	
Q1	2 Point average: $(\text{CE ending Q4 Prior year} + \text{CE ending Q1}) / 2$
Q2	2 Point average: $(\text{CE ending Q1} + \text{CE ending Q2}) / 2$
Q3	2 Point average: $(\text{CE ending Q2} + \text{CE ending Q3}) / 2$
Q4	2 Point average: $(\text{CE ending Q3} + \text{CE ending Q4}) / 2$

* NCE for Operations Groups

Reconciliation and Definitions for Non-GAAP Measures (II)

Our cash target is based on the **Cash Conversion Rate (CCR)**, which serves as a target indicator for the Company's or the Group's cash flow. For the Company, CCR is defined as the ratio of Free cash flow to Net income, where Free cash flow equals the Net cash provided by (used in) operating activities less Additions to intangible assets and property, plant and equipment.

Because Siemens reports discontinued operations, this measure is also shown on a continuing operations basis, using Income from continuing operations, Net cash provided by (used in) operating activities – continuing operations and Additions to intangible assets and property, plant and equipment for continuing operations for the calculation.

For the Groups, CCR is defined as Free cash flow divided by Group profit.

All values needed for the calculation of ROCE and CCR can be obtained from the Consolidated Financial Statements and Notes to Consolidated Financial Statements.

Group profit, Net capital employed and Free cash flow for the Company and the Groups can be found on the table Segment information. Our Consolidated Financial Statements are available on our Investor Relations website under www.siemens.com.

Siemens ties a portion of its executive incentive compensation to achieving **economic value added (EVA)** targets. EVA measures the profitability of a business (using Group profit for the Operating Groups and Income before income taxes for the Financing and Real estate businesses as a base) against the additional cost of capital used to run a business (using NCE for the Operating Groups and risk-adjusted equity for the Financing and Real estate businesses as a base). A positive EVA indicates that a business has earned more than its cost of capital, and is therefore defined as value-creating. A negative EVA indicates that a business is earning less than its cost of capital and is therefore defined as value-destroying. Other organizations that use EVA may define and calculate EVA differently.


To measure Siemens' achievement of the **goal to grow at twice the rate of global GDP**, we use GDP on real basis (i.e. excluding inflation and currency translation effects) with data provided by Global Insight Inc. and compare those growth rates with growth rates of our revenue (under IFRS). In accordance with IFRS, our revenue numbers are not adjusted by inflation and currency translation effects.

Return on equity (ROE) margin for SFS was calculated as SFS' Income before income taxes divided by the allocated equity for SFS. Allocated equity for SFS for the financial year 2007 is €1.041 billion.

The allocated equity for SFS is determined and influenced by the respective credit ratings of the rating agencies and by the expected size and quality of its portfolio of leasing and factoring assets and equity investments and is determined annually. This allocation is designed to cover the risks of the underlying business and is in line with common credit risk management standards in banking. The actual risk profile of the SFS portfolio is monitored and controlled monthly and is evaluated against the allocated equity.

Backup


Building the first integrated diagnostics company worldwide



Presence in all diagnostic market segments is an important enabler for integrating clinical workflow and clinical information, in order to realize the vision of knowledge-driven healthcare

Dade Behring is a unique opportunity to reach a #1 position in IVD

IVD¹⁾ Revenue 2006 (in € bn)




1) IVD: In vitro Diagnostics; Source: IVD Market model DX, 2006. Roche revenue, excl. Diabetes Care and Applied Science

Siemens in third quarter of FY 2007

- **Fit for 2010** successfully started
- Group profit climbed **22%** to **€1.504 bn**
- Revenue increased **8%** to **€20.176 bn**
- New orders grew **13%** to **€22.147 bn**

Significant investment in portfolio and benefits to shareholders



1) reflecting enterprise values resp. cash outflow, for Dade Behring approx. value, all values pretax; exchange rates monthly averages, UGS: May 2007, Dade Behring: July 2007

2) as of June 30, 2007